Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
SOUTH SAN FRANCISCO, Calif., May 01, 2018 -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Tuesday, May 8th, 2018 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March 31, 2018.
The call can be accessed by dialing (844) 296-7720 (U.S. and Canada) or (574) 990-1148 (international) and entering passcode 9676198.
To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://ir.sunesis.com. The webcast will be recorded and available for replay on the company's website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company developing new therapeutics for the treatment of solid and hematologic cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that its oral non-covalent BTK-inhibitor vecabrutinib is effective in ibrutinib-resistant chronic lymphocytic leukemia. Vecabrutinib is currently being evaluated in a Phase 1b/2 study in adults with chronic lymphocytic leukemia and other B-cell malignancies who have progressed after prior therapies. Beyond the development of vecabrutinib, the Company has two other kinase inhibitor programs, including the Takeda-partnered pan-RAF inhibitor TAK-580, which is in clinical trials for solid tumors, and Sunesis’ proprietary preclinical PDK1 inhibitor SNS-510, which is in preclinical development with an IND submission planned in 2019. PDK1 is a master kinase that activates other kinases important to cell growth and survival including members of the AKT, PKC, RSK and SGK families.
For additional information on Sunesis, please visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
| Investor and Media Inquiries: | ||
| Maeve Conneighton | Willie Quinn | |
| Argot Partners | Sunesis Pharmaceuticals Inc. | |
| 212-600-1902 | 650-266-3716 | |
